Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzyl Benzoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Benzoate SCHEMBL27589165 | 0.92 | TDP1 (0.92) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL3038 | 0.92 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL901058 | 0.92 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL8010992 | 0.92 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL9058384 | 0.91 | TDP1 (0.82) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL28620326 | 0.91 | TDP1 (0.82) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL19180300 | 0.91 | TDP1 (0.89) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL20681635 | 0.91 | TDP1 (0.89) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL28162328 | 0.91 | TDP1 (0.89) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL29101943 | 0.90 | KMT2A (0.96) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240011977-A1 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. | 2024-01-11 | — | — | US | claimed |
| WO-2024011121-A2 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. (US) | 2024-01-11 | — | — | WO | claimed |
| WO-2021063609-A1 | BISMUTH OXYCHLORIDE-CONTAINING SUNSCREEN FOR PROTECTION FROM BLUE LIGHT | BEIERSDORF AG (DE) | 2021-04-08 | — | — | WO | claimed |
| CN-118286146-A | Local anesthetic lipid conjugate in-situ gel preparation and preparation method thereof | 浙江大学 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024125179-A1 | CHAOTROPES-ASSISTED DEEP IMMUNOSTAINING | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199857-A1 | CHAOTROPES-ASSISTED DEEP IMMUNOSTAINING | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240139212-A1 | ABIRATERONE PRODRUGS | ASTELLAS US LLC | 2024-05-02 | — | — | US | disclosed |
| US-11957696-B2 | Abiraterone prodrugs | PROPELLA THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024071029-A1 | METHOD FOR PRODUCING TRANSPARENTIZED BIOLOGICAL SPECIMEN | 学校法人金沢医科大学 | 2024-04-04 | — | — | WO | disclosed |
| US-20240050447-A1 | ABIRATERONE PRODRUGS | ASTELLAS US LLC | 2024-02-15 | — | — | US | disclosed |
| WO-2024011121-A2 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-6376542-B1 | IN BENZYL ALCOHOL SOLVENT | BISSELL HOMECARE, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1192268-A2 | NUCLEIC ACID BINDING OF MULTI-ZINC FINGER TRANSCRIPTION FACTORS | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE) | 2002-04-03 | — | — | EP | disclosed |
| EP-1117986-A1 | METHOD FOR IMAGING TISSUE | Rogers Imaging Corporation (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6232092-B1 | Method for preparing biological specimens for visual analysis | ROGERS IMAGING CORPORATION | 2001-05-15 | — | — | US | disclosed |
| WO-2000020846-A9 | METHOD FOR IMAGING TISSUE | ROGERS IMAGING CORP (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001000864-A2 | NUCLEIC ACID BINDING OF MULTI-ZINC FINGER TRANSCRIPTION FACTORS | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000020846-A1 | METHOD FOR IMAGING TISSUE | ROGERS IMAGING CORPORATION (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-1998016641-A1 | ISOLATION AND METHOD OF USING TISSUE GROWTH-INDUCING FRZB PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5693779-A | ISOLATED POLYNUCLEOTIDE ENCODING PROTEIN USEFUL FOR TREATING OR PREVENTING SYNDROMES INVOLVING INAPPROPRIATE TISSUE PROLIFERATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139212-A1 | ABIRATERONE PRODRUGS | SHBG, CYP21A2, CYP17A1 | TDP1 1324/4885KMT2A 3855/4885SLC6A2 282/4885 |
| US-11957696-B2 | Abiraterone prodrugs | SHBG, CYP21A2, CYP17A1 | TDP1 1324/4885KMT2A 3855/4885SLC6A2 282/4885 |
| US-20240050447-A1 | ABIRATERONE PRODRUGS | CYP21A2, SHBG, CYP17A1 | TDP1 855/4885KMT2A 4080/4885SLC6A2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.